Home » Stocks » TCON

TRACON Pharmaceuticals, Inc. (TCON)

Stock Price: $6.46 USD 0.25 (4.03%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 100.14M
Revenue (ttm) n/a
Net Income (ttm) -17.82M
Shares Out 15.48M
EPS (ttm) -1.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $6.46
Previous Close $6.21
Change ($) 0.25
Change (%) 4.03%
Day's Open 6.17
Day's Range 6.17 - 6.69
Day's Volume 91,108
52-Week Range 1.55 - 12.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

TRACON Pharmaceuticals Inc (NASDAQ:TCON) ended the first quarter of 2021 on March 31 with cash and equivalents of $30.4 million, which it said will fund its operations into the second half of 2022. The ...

4 days ago - Proactive Investors

SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer the...

4 days ago - GlobeNewsWire

SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

6 days ago - GlobeNewsWire

SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

1 week ago - GlobeNewsWire

NEW YORK, April 26, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty c...

1 week ago - PRNewsWire

Clinical-stage pipeline includes envafolimab to treat soft-tissue sarcoma Awarded Orphan Drug designation for TRC102 to treat brain and spinal cord cancers Looking for partnerships to help with regulato...

1 month ago - Proactive Investors

Poster to Highlight ENVASARC Pivotal Trial Evaluating Envafolimab in Sarcoma Poster to Highlight ENVASARC Pivotal Trial Evaluating Envafolimab in Sarcoma

1 month ago - GlobeNewsWire

SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...

2 months ago - GlobeNewsWire

TRACON Pharmaceuticals Inc (NASDAQ:TCON) said it has appointed Dr Lisa Johnson-Pratt to the company's board of directors. TRACON noted that Dr Johnson-Pratt brings more than two decades of broad busines...

2 months ago - Proactive Investors

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeu...

2 months ago - GlobeNewsWire

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...

2 months ago - GlobeNewsWire

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

2 months ago - GlobeNewsWire

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

2 months ago - GlobeNewsWire

NDA was Submitted in November by TRACON's Corporate Partners, Alphamab Oncology and 3D Medicines, in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submitted in Nov...

3 months ago - GlobeNewsWire

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

4 months ago - GlobeNewsWire

NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal a...

4 months ago - GlobeNewsWire

SAN DIEGO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

4 months ago - GlobeNewsWire

SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

4 months ago - GlobeNewsWire

Company Expects Interim Data in Mid-2021 Company Expects Interim Data in Mid-2021

4 months ago - GlobeNewsWire

Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors.

Other stocks mentioned: ARPO, RGEN
5 months ago - Zacks Investment Research

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

5 months ago - GlobeNewsWire

Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastr...

5 months ago - GlobeNewsWire

TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

5 months ago - GlobeNewsWire

SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

6 months ago - GlobeNewsWire

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

6 months ago - GlobeNewsWire

TRACON’s Pivotal ENVASARC Trial of envafolimab in the Sarcoma Subtypes of UPS and MFS Expected to Initiate Dosing in 4Q 2020 TRACON’s Pivotal ENVASARC Trial of envafolimab in the Sarcoma Subtypes of UPS...

7 months ago - GlobeNewsWire

SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cance...

7 months ago - GlobeNewsWire

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cance...

8 months ago - GlobeNewsWire

SAN DIEGO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer...

8 months ago - GlobeNewsWire

SAN DIEGO, Aug. 27, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer...

8 months ago - GlobeNewsWire

Dosing in Pivotal Trial Expected to Begin in Fourth Quarter of 2020 in the U.S. Dosing in Pivotal Trial Expected to Begin in Fourth Quarter of 2020 in the U.S.

8 months ago - GlobeNewsWire

TRACON Pharmaceuticals' (TCON) CEO Charles Theuer on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer...

9 months ago - GlobeNewsWire

SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...

9 months ago - GlobeNewsWire

Dosing in Pivotal Trial Expected to Begin in Second Half of 2020 at 25 Sites in the U.S. Dosing in Pivotal Trial Expected to Begin in Second Half of 2020 at 25 Sites in the U.S.

9 months ago - GlobeNewsWire

Webinar to be held on Friday, July 17, at 11:00 AM Eastern Time Webinar to be held on Friday, July 17, at 11:00 AM Eastern Time

9 months ago - GlobeNewsWire

SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer...

11 months ago - GlobeNewsWire

Undifferentiated Pleomorphic Sarcoma is the Major Sarcoma Subtype to be Enrolled in TRACON’s Pivotal ENVASARC Trial  of Envafolimab as a Single Agent and in Combination with Yervoy

11 months ago - GlobeNewsWire

TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

11 months ago - GlobeNewsWire

Company Reaches Agreement with Regulatory Agency on Key Elements  of ENVASARC Trial

11 months ago - GlobeNewsWire

TRACON seeks licensing partner to develop and commercialize TRC253 in China TRACON seeks licensing partner to develop and commercialize TRC253 in China

1 year ago - GlobeNewsWire

SAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therap...

1 year ago - GlobeNewsWire

SAN DIEGO, March 19, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therap...

1 year ago - GlobeNewsWire

SAN DIEGO, March 16, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therap...

1 year ago - GlobeNewsWire

OSAKA, Japan and SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; hereinafter, “Santen”) and TRACON Pharmaceuticals, Inc. (Head Office: San Diego, CA;...

1 year ago - GlobeNewsWire

TRACON Pharmaceuticals Inc. (TCON) CEO Charles Theuer on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

SAN DIEGO, Feb. 07, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therape...

1 year ago - GlobeNewsWire

Shares of Tracon Pharmaceuticals Inc. TCON, -4.23% were up 29% in premarket trading on Friday after the company said it would partner with two Chinese companies to develop its investigational soft tissu...

1 year ago - Market Watch

About TCON

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clini... [Read more...]

Industry
Biotechnology
IPO Date
Jan 30, 2015
Stock Exchange
NASDAQ
Ticker Symbol
TCON
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for TCON stock is "Buy." The 12-month stock price forecast is 14.83, which is an increase of 129.57% from the latest price.

Price Target
$14.83
(129.57% upside)
Analyst Consensus: Buy